Research shows that the drug Imatinib, usually prescribed for Leukemia and gastric cancer, halves mortality and shortens the stay of Covid patients at the ICU by a week. Imatinib is especially effective in the 20 percent most ill Covid patients. However, further research is needed. Follow-up studies will be done by Amsterdam OLVG, the Erasmus Medical Center, the Dijklander Hospital and by the World Health Organisation in the Remapcap study.
Read more (in Dutch)
Are you looking for a testing ground for your innovation? SAIL and the Amsterdam Marathon present an excellent opportunity to test your ideas. These major events attract millions of visitors and come with sustainability, accessibility, and logistical challenges that need fresh solutions. The In Residence Events program allows you to test your innovation during these […]
NewsWater, comprising over 70% of our planet, is the source of all life. The presence of emerging contaminants in our water, including pharmaceuticals, pose serious health and environmental risks, such as DNA damage, reproductive issues, and cancer. New equipment to detect these contaminants developed by VU researchers has been sold to other research groups all over the world. Now the researchers are taking the next step, together with IXA, to expand sales to water companies worldwide as well as other applications such as food and drug discovery research.
NewsThe Academic Workplace Rudolf Berlin Center (AW RBC) aims to make a meaningful contribution by supporting young people with learning disabilities through enhanced education and care.
News